<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01178996</url>
  </required_header>
  <id_info>
    <org_study_id>ST1472-DM-03-004</org_study_id>
    <secondary_id>2004-001277-25</secondary_id>
    <nct_id>NCT01178996</nct_id>
  </id_info>
  <brief_title>Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.</brief_title>
  <official_title>A Phase III, Multicentre, Double Blinded Study In Patients With Chronic Hepatitis C Who Are Non-Responders To Prior Peginterferon Alpha + Ribavirin Therapy Comparing Treatment With Thymosin Alpha 1 + Peginterferon Alpha-2a Plus Ribavirin With Peginterferon Alpha-2a + Ribavirin + Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>sigma-tau i.f.r. S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SciClone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>sigma-tau i.f.r. S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to determine safety and efficacy of 48 weeks treatment with
      Thymosin alpha 1 (Talpha1) in combination with pegylated interferon (PEGIFN) alpha2a and
      ribavirin (RBV) in adult patients with chronic hepatitis C (CHC) already treated with, and
      not responding to previous courses of PEGIFN alpha plus RBV combination therapy, in
      comparison with a concurrent group treated with PEG IFN alpha2a in combination with RBV and
      placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Virological Response (SVR)</measure>
    <time_frame>Week 72</time_frame>
    <description>The proportion of patients who were HCV RNA negative at the end of observation period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sustained Biochemical Response (SBR)</measure>
    <time_frame>Week 72</time_frame>
    <description>The proportion of patients with normal serum ALT at the end of observation period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of Treatment Biochemical Response (EBR)</measure>
    <time_frame>Week 48</time_frame>
    <description>The proportion of patients with normal serum ALT at the end of treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>End of Treatment Virological Response [EVR]</measure>
    <time_frame>Week 48</time_frame>
    <description>The proportion of patients who were HCV RNA negative at the end of treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>During the treatment period (up to 48 weeks) and the follow-up period (up to 24 weeks)</time_frame>
    <description>Safety and tolerability were evaluated by AEs recording, laboratory (hematology and chemistry), ECG, and vital signs evaluations. All laboratory tests were centralized.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">552</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Thymosin alpha 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients affected by chronic hepatitis C not responding to a course with approved doses of PEGinterferon alpha plus ribavirin therapy (i.e. at least 1.0 mcg/kg PEGinterferon alpha2b, 180 mcg PEGinterferon alfa2a, 800 mg ribavirin).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Thymosin alpha 1</intervention_name>
    <description>Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.</description>
    <arm_group_label>Thymosin alpha 1</arm_group_label>
    <other_name>Zadaxin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>Ribavirin 1000 mg (&lt;75 kg) or 1200 mg (&gt;75 kg) daily with food divided in two doses orally for 48 weeks</description>
    <arm_group_label>Thymosin alpha 1</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Copegus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PEGinterferon alfa2a</intervention_name>
    <description>180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks</description>
    <arm_group_label>Thymosin alpha 1</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Pegasys</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent

          2. Age 18

          3. Presence of HCV RNA measured by quantitative PCR

          4. Non responder to previous approved doses of therapy with PEGinterferon alpha plus
             ribavirin. Patients must have been treated for at least 12 weeks with documented HCV
             RNA quantitative not showing major of 2 log10 HCV RNA reduction or patients treated
             for at least 24 weeks with documented HCV RNA qualitative not showing a virological
             response (viral RNA clearance)

          5. Liver biopsy consistent with a diagnosis of chronic hepatitis C or histological
             cirrhosis. Biopsy will not be required if the patient can produce a biopsy performed
             within the year preceding the randomization day and was performed at least 6 months
             after the end of the latter course of therapy

          6. Wash-out period of at least 6 months from previous therapy with PEGinterferon alpha
             plus ribavirin

          7. Negative pregnancy test prior (no more than 24 hours) to first study medication dose

        Exclusion Criteria:

          1. Use of systemic corticosteroids within 6 months of entry

          2. More than one previous course of therapy with PEGinterferon alpha plus ribavirin

          3. Any other liver disease

          4. Decompensated liver disease based on a history of hepatic encephalopathy, bleeding
             oesophageal varices, or ascites

          5. Decompensate or advanced liver cirrhosis (ChildPugh B or C)

          6. HIV infection diagnosed by HIV seropositivity and confirmed by Western blot

          7. Insulin-dependent Diabetes Mellitus

          8. Severe haemoglobinopathy

          9. Positive liver and kidney microsomal auto antibodies

         10. Positive anti thyroid antibodies

         11. Pregnancy as documented by a urine pregnancy test

         12. Alcohol or intravenous drug abuse within the previous 1 year

         13. Patients who are in poor medical or psychiatric conditions, or who have any
             non-malignant systemic disease that, in the opinion of the Investigator, would make it
             unlikely that the patient could complete the study protocol

         14. Any indication that the patient would not comply with the conditions of the study
             protocol

         15. Previous treatment with thymosin alpha 1

         16. Patients with known hypersensitivity to any PEGinterferon and or ribavirin

         17. Patients with a history of severe depression that required either hospitalization or
             electroshock therapy or depression associated with suicide attempt

         18. Simultaneous participation in another investigational drug study or participation in
             any clinical trial involving investigational drugs within 3 months before study entry

         19. Presence of serious pulmonary or cardiovascular disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mario Rizzetto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dipartimento Medico Chirurgico delle Malattie dell'Apparato Digerente e della Nutrizione, Azienda Ospedaliera S Giovanni Battista, Corso Bramante 88, Turin, Italy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75743</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Tübingen</name>
      <address>
        <city>Tübingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>45 500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dipartimento Medico Chirurgico delle Malattie dell'Apparato Digerente e della Nutrizione, Azienda Ospedaliera S Giovanni Battista</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 9, 2010</study_first_submitted>
  <study_first_submitted_qc>August 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 10, 2010</study_first_posted>
  <last_update_submitted>August 9, 2010</last_update_submitted>
  <last_update_submitted_qc>August 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2010</last_update_posted>
  <responsible_party>
    <name_title>Alfonso De Rosa Clinical Research Manager</name_title>
    <organization>Sigma-tau SPA</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Peginterferon alfa-2b</mesh_term>
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

